Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

IMV Inc. Announces Third Quarter 2021 Financial and Operational Update


IMV Inc. ("IMV" or "the Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing immune-educating cancer therapies, based on its novel DPX platform, that target solid and blood cancers while preserving patients' quality of life, today announced its financial and operational results and provided an update for the third quarter ended September 30, 2021.

"IMV is undergoing a pivotal transformation. We are realigning IMV's strategy to focus on its core competencies in immuno-oncology. We intend to move maveropepimut-S (MVP-S) forward on the path to registrational trials and to leverage our versatile DPX platform to further develop a comprehensive portfolio of cancer immunotherapies, both in-house and with partners. As we explore the potential of our DPX delivery platform and the development of new DPX-based candidates, we are actively evaluating potential licensing opportunities for our programs outside of immuno-oncology," said Andrew Hall, interim Chief Executive Officer of IMV.

"Our recent clinical results and translational data are promising and demonstrate the potential of our lead compound in both solid and blood tumors. MVP-S continues to be well-tolerated across indications. We have seen sustained response in patients who had already gone through many lines of previous treatments." Mr. Hall continued. "Additionally, our second immunotherapy candidate, DPX-SurMAGE, has shown encouraging results in preclinical studies and demonstrates the platform's potential to deliver across multiple therapeutic targets. Together, we believe that these results clearly support the expansion of our clinical oncology pipeline across a wider range of tumor antigens and indications both through in-house efforts and an acceleration of business development initiatives."

CLINICAL UPDATE

Maveropepimut-S (MVP-S)

IMV recently completed the DeCidE1 clinical trial evaluating MVP-S in association with low dose intermittent cyclophosphamide (CPA) in patients with advanced recurrent ovarian cancer. As announced in early August, the overall survival rate was 44.9% with a median overall survival of 19.9 months in a heavily pre-treated population at the two-year cut-off.

These results support further clinical evaluation. IMV expects to initiate a Phase 2B clinical trial in 2022.

DPX-SurMAGE in Bladder Cancer

Yves Fradet, M.D., Professor, Department of Surgery at the Faculty of Medicine, Université Laval in Quebec City presented preclinical data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, showing that the DPX delivery platform can be leveraged to develop novel multi-targeted T-cell activating immunotherapies.

More specifically, these studies showed that it was possible to simultaneously elicit immune responses against two cancer antigens (survivin and MAGE-A9 proteins) in bladder cancer model.

The addition of intermittent low dose cyclophosphamide (CPA) did not significantly change the immune response. DPX-SurMAGE was well-tolerated in the preclinical models.

Based on these results, IMV is currently optimizing the design of a Phase 1 trial in non-muscle invasive bladder cancer patients which is expected to begin by year-end.

Foundational Research

A second poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics described that antigenic peptides, when packaged within the DPX platform, elicit specific T cell-based immune responses in a more robust and persistent manner than conventional water-based formulations.

CORPORATE UPDATE

Overview of Third Quarter 2021 Financial Results

All dollar amounts noted herein are denominated in United States dollars (unless otherwise noted herein).

On September 30, 2021, the Company had cash and cash equivalents of $36.5 million and working capital of $37.3 million, compared with $36.3 million and $35.6 million, respectively at December 31, 2020. This increase primarily reflects net proceeds from the $25 million public offering completed on July 20, 2021, offset by cash used in operations year to date. Based on its current plan, IMV expects its current cash position will be sufficient to fund operations until Q3 2022.

Research and development expenses were $5.6 million for the three months ended September 30, 2021, compared with $4.9 million for the three months ended September 30, 2020. This increase of $0.7 million was mainly due to start-up costs for the Phase 2B VITALIZE study, an increase in manufacturing and development costs for MVP-S and an increase in headcount. These increases were partly offset by a decrease in development costs for DPX-COVID-19 following a shift in strategic focus.

General and administrative expenses were $5.3 million for the three months ended September 30, 2021, compared with $2.8 million for the three months ended September 30, 2020. This increase of $2.5 million was mainly attributable to an increase in salaries and non-cash stock-based compensation associated with planned hiring and executive leadership changes, foreign currency loss and, to a lesser extent, an increase in legal, professional, and recruitment fees.

Government assistance totaled $0.5 million for the three months ended September 30, 2021, compared with $1.3 million in Q3 2020. This decrease is mainly driven by a decrease in funding related to DPX-COVID-19 development costs.

The net loss and comprehensive loss of $10.4 million ($0.13 per share) for the three months ended September 30, 2021, was $5 million higher than the net loss and comprehensive loss of $5.4 million ($0.08 per share) for the three months ended September 30, 2020.

For the nine-month period ended September 30, 2021, the net loss and comprehensive loss of $24.9 million ($0.35 per share) was $7.5 million higher than the net loss and comprehensive loss of $17.4 million ($0.30 per share) for the nine-month period ended September 30, 2020.

As of November 10, 2021, the number of issued and outstanding common shares was 82,142,629 and a total of 16,289,495 stock options, warrants and deferred share units were outstanding.

The Corporation's audited annual consolidated results of operations, financial condition and cash flows for the year ended December 31, 2020, and the related management's discussion and analysis (MD&A) are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar as well as the Company's website at www.imv-inc.com

SELECTED UPCOMING MILESTONES

Maveropepimut-S (MVP-S):

DPX-SurMAGE:

Conference Call and Webcast Information

Management will host a conference call and webcast today November 11, 2021, at 8:00 a.m. ET. Financial analysts are invited to join the conference call by dialing (866) 211-3204 (U.S. and Canada) or (647) 689-6600 (international) using the conference ID# 7079735

Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations. The webcast will be recorded and will then be available on the IMV website for 30 days following the call.

About IMV

IMV Inc. is a clinical stage biotechnology company developing a portfolio of immune-educating cancer therapies, based on its novel DPX platform, to treat solid and blood cancers while preserving patients' quality of life. We are dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing hard-to-treat cancers We are committed to developing a new class of immunotherapies that balance tolerability and efficacy to treat cancer. The Company is developing a portfolio of novel therapies based on DPX, its versatile immune-educating technology platform, that drives a specific, robust, well-tolerated and persistent anti-tumor immune response, potentially offering long-lasting benefit to patients with solid or blood cancers. IMV's lead compound, maveropepimut-S (MVP-S) is currently being evaluated in a range of oncology applications including neoadjuvant and checkpoint combination settings. MVP-S demonstrated clinical benefit in patients with difficult-to-treat cancers; and safety and tolerability have been seen in more than 350 patients.

IMV is also developing another DPX-based immunotherapy: DPX-SurMAGE, a dual targeted immunotherapy being evaluated in subjects with bladder cancer. For more information, visit www.imv-inc.com and connect with us on Twitter and LinkedIn.

IMV Forward-Looking Statements

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as "will", "may", "potential", "believe", "expect", "continue", "anticipate" and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the ability of the DPX delivery platform to elicit robust immune responses; the versatility and potential of the DPX delivery platform to treat a wide range of diseases generally; the potential for partnering opportunities for IMV with respect to its various immunotherapies; and the timing of commencement and expected results from IMV's various clinical trials and studies. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful design and completion of clinical trials and the timely receipt of all regulatory approvals to commence, and then continue, clinical studies and trials and the receipt of all regulatory approvals to commercialize its products. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, the ability to access capital, the successful and, generally, the timely completion of clinical trials and studies and the receipt of all regulatory approvals as well as other risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar

IMV INC.
Consolidated Statements of Loss and Comprehensive Loss

(In thousands of United States dollars, except for share and per share amounts)

 

 

 

 

 

 

 

 

 

Three Months ended,

September 30,

 

Nine Months ended,

September 30,

 

2021

$

 

2020

$

 

2021

$

 

2020

$

Revenue

 

 

 

 

 

 

 

Interest Income

41

 

66

 

153

 

157

Total revenue

41

 

66

 

153

 

157

Expenses

 

 

 

 

 

 

 

Research and development

5,635

 

4,911

 

15,601

 

13,767

General and administrative

5,260

 

2,777

 

11,844

 

7,227

Government assistance

(476)

 

(1,264)

 

(2,875)

 

(2,697)

Accreted interest and valuation adjustments

61

 

(106)

 

436

 

528

Total operating expenses

10,480

 

6,318

 

25,006

 

18,825

Net loss

(10,439)

 

(6,252)

 

(24,853)

 

(18,668)

Currency translation adjustment

-

 

844

 

-

 

1,268

Total comprehensive loss

(10,439)

 

(5,408)

 

(24,853)

 

(17,400)

Basic and diluted loss per share

(0.13)

 

(0.08)

 

(0.35)

 

(0.30)

Weighted-average shares outstanding

79,175,74

 

65,970,26

 

71,520,47

 

58,025,98

 

 

 

 

 

 

 

 

IMV INC.
Consolidated Statements of Financial Position

(In thousands of United States dollars, except for share and per share amounts)

 

 

September 30,

2021

 

December 31,

2020

Assets

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

$

36,495

 

$

36,268

Accounts receivable

 

1,137

 

 

1,574

Prepaid expenses

 

7,866

 

 

4,416

Investment tax credits receivable

 

725

 

 

1,519

Total current assets

 

46,223

 

 

43,777

Property and equipment

 

3,340

 

 

2,221

Total assets

$

49,563

 

$

45,998

 

Liabilities and Equity

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable, accrued and other liabilities

$

8,557

 

$

7,228

Current portion of long-term debt

 

76

 

 

856

Current portion of lease obligations

 

259

 

 

109

Total current liabilities

 

8,892

 

 

8,193

Lease obligation

 

1,453

 

 

953

Long-term debt

 

6,448

 

 

6,050

Total liabilities

 

16,793

 

 

15,196

Equity

 

32,770

 

 

30,802

Total liabilities and equity

$

49,563

 

$

45,998

 


These press releases may also interest you

at 10:41
"Hate always terrorizes. That's the intention. As an African American woman who came of age during the Civil Rights era, I know at heart how hate works to harm some and paralyze or, at least, to immobilize others. But movement is life. It's certainly...

at 10:30
The "Introduction to the In-Vitro Diagnostic Regulation (IVDR) Training Course" conference has been added to ResearchAndMarkets.com's offering. The In-Vitro Diagnostic Regulation (EU) 2017/746, which came into force in May 2017 with a transition...

at 10:30
Najah Sampson has been named President of Pfizer Canada ULC, effective May 16, 2022. Ms. Sampson will be succeeding Cole Pinnow, who...

at 10:30
The global Ibuprofen API Market surpassed US$ 626.2 Mn in 2022 and is anticipated to increase at a CAGR of 3% to reach US$ 772.2 Mn by 2029. as per the findings of a...

at 10:30
The "Hospital Lights Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Technology and Application" report has been added to ResearchAndMarkets.com's offering. The Hospital Lights market is expected to grow from US$...

at 10:20
The Cryogenic PPE Market size is expected to grow by USD 426.23 million from 2021 to 2026, at a CAGR of 6.52% during the forecast period. The expanding applications in healthcare and life sciences is one of the primary aspects driving the cryogenic...



News published on 10 november 2021 at 17:10 and distributed by: